HealthStream: Solid Q4 Beat, Durable Subscription-Driven Growth, and Platform Strategy Underpin Buy Rating

William Blair analyst Ryan Daniels has maintained their bullish stance on HSTM stock, giving a Buy rating on February 20.

Ryan Daniels has given his Buy rating due to a combination of factors, including HealthStream’s stronger‑than‑expected fourth‑quarter results and encouraging 2026 outlook. The company outperformed consensus on both revenue and adjusted EBITDA, and management’s revenue guidance for the coming year points to continued mid‑single‑digit growth driven primarily by subscription sales.

Daniels also highlights a healthy sales pipeline, rising bookings, and expanding remaining performance obligations as evidence of durable demand for HealthStream’s solutions, even as some legacy products create temporary headwinds. He believes the firm’s evolving platform strategy, combined with a growing clinician workforce and its entrenched role in compliance‑driven healthcare education, supports long‑term growth and monetization, justifying the Buy recommendation.